THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?

BackgroundSecondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies.ObjectivesTo describe and compare demographics, clinical and l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.396
Hauptverfasser: Egües Dubuc, C.A., Aldasoro Cáceres, V., Uriarte Ecenarro, M., Meneses Villalba, C.F., Errazquin Aguirre, N., Hernando Rubio, I., Maiz Alonso, O., Cancio Fanlo, J., Uriarte Isacelaya, E., Yagüe Asensio, M., Belzunegui Otano, J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 396
container_title Annals of the rheumatic diseases
container_volume 74
creator Egües Dubuc, C.A.
Aldasoro Cáceres, V.
Uriarte Ecenarro, M.
Meneses Villalba, C.F.
Errazquin Aguirre, N.
Hernando Rubio, I.
Maiz Alonso, O.
Cancio Fanlo, J.
Uriarte Isacelaya, E.
Yagüe Asensio, M.
Belzunegui Otano, J.
description BackgroundSecondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies.ObjectivesTo describe and compare demographics, clinical and laboratories features and mortality of patients diagnosed with secondary MAS due to HO and AI diseases at the Donostia University Hospital.MethodsA cohort of patients diagnosed with MAS was studied by reviewing medical reports in the period Dec/2008-Jan/2015. We analyzed and compared only patients with AI and HO diseases. The variable studied were diagnosis, age, sex, fever, organomegaly, hospital and overall mortality, analytical findings, hospital stay, days from admission to diagnosis and days from diagnosis to the end of the study or death after discharge. Quantitative variables are shown with the median and interquartile range. For the bivariate analysis Wilcoxon and Chi square test were used. Median survival in months and Hazar Ratio (HR) was calculated with the Kaplan Meier plot.ResultsNineteen patients were found diagnosed with MAS, 6 and 9 were due to AI and HO diseases respectively. The AI diseases found were: 3 Systemic Lupus Erythematosus, 2 Adult Still's Disease and 1 disease associated with IgG4. HO diseases found were: 3 acute myeloid leukemias, 2 B cells Not Hogkin Lymphoma (NHL), 1 T anb B cells NHL, 1 Natural Killers cells extranodal lymphoma, 1 myelodysplastic syndrome and 1 gastric plasmacytoma. The table shows the descriptive analysis of 19 patients and the bivariate analysis between AI and HO.The median survival of HO diseases was 1.2 months and AI diseases can not be calculated. The mortality of HO and AI diseases was 77.8% and 16.7% respectively with a p=0.04 in the log rank test. The HR of mortality among HO against AI diseases was 6.84.Table 1All patientsAI diseaseOH diseasep between AI and HOAge (years)56 (32)37.5 (26)66 (15)Female Sex10 (52.6%)4 (66.7%)4 (66.7%)0.205Hospitalization Days from admission to diagnosis38 (69)37.5 (46)61 (59)0.216Days from diagnosis until death or end of study430 (1166)1125 (554)67.5 (410)0.07Organomegaly15 (78.9%)5 (83.3%)7 (77.8%)0.792Hemoglobin (mg/dL)7.3 (1.6)7.4 (2.5)6.4 (1.1)0.0866Platelets (/μL)8000 (15000)11000 (66000)2000 (15000)0.0771Leukocytes (/μL)1010 (2990)2840 (1850)100 (590)0.0771Neutrophils (/μL)360 (1770)1068 (1120)0 (20)0.0074Triglycerides (mg/dL)382 (217)414.5 (307)341 (157)0.44Fibrinogen
doi_str_mv 10.1136/annrheumdis-2015-eular.3006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901786923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322503671</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1273-d42c841daadc8a981e84043728c5149719f762e69ab4f52a68162737b912083</originalsourceid><addsrcrecordid>eNqVkb9OwzAQxi0EEqXwDpaYA7bjOo4YUIHSVipiKMyWm1xaV41d7ASUjYWX4PF4ElzKwMp0f3Tfd3f6IXROyQWlqbjU1voVtHVpQsIIHSTQbrS_SAkRB6hHuZCxLcgh6hFC0oTnIjtGJyGsY0kklT30-TR5JgPOvt4_pgE3K_CAh7bDd6aqYm4LwDfQvAFYPGwbZ-q6tYCdxxOodeOSR1u4jVt2eNSYfdI4PG5NCbgN2NidZTTTS-uCCdhVeA6Fs6X2HX7QhXfblV7GlUVjXnW0sHje2dK7Gq5P0VGlNwHOfmMfze9HT7eTZPY4nt4OZ8mCsixNSs4KyWmpdVlInUsKkhOeZkwWA8rzjOZVJhiIXC94NWBaSCqiLlvklBGZ9tH53nXr3UsLoVFr13obFyqaE5pJkbM0Tl3tp-LFIXio1NabOj6hKFE7FOoPCrVDoX5QqB2KqBZ79aJe_0v4DahBlkQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901786923</pqid></control><display><type>article</type><title>THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?</title><source>BMJ Journals - NESLi2</source><creator>Egües Dubuc, C.A. ; Aldasoro Cáceres, V. ; Uriarte Ecenarro, M. ; Meneses Villalba, C.F. ; Errazquin Aguirre, N. ; Hernando Rubio, I. ; Maiz Alonso, O. ; Cancio Fanlo, J. ; Uriarte Isacelaya, E. ; Yagüe Asensio, M. ; Belzunegui Otano, J.</creator><creatorcontrib>Egües Dubuc, C.A. ; Aldasoro Cáceres, V. ; Uriarte Ecenarro, M. ; Meneses Villalba, C.F. ; Errazquin Aguirre, N. ; Hernando Rubio, I. ; Maiz Alonso, O. ; Cancio Fanlo, J. ; Uriarte Isacelaya, E. ; Yagüe Asensio, M. ; Belzunegui Otano, J.</creatorcontrib><description>BackgroundSecondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies.ObjectivesTo describe and compare demographics, clinical and laboratories features and mortality of patients diagnosed with secondary MAS due to HO and AI diseases at the Donostia University Hospital.MethodsA cohort of patients diagnosed with MAS was studied by reviewing medical reports in the period Dec/2008-Jan/2015. We analyzed and compared only patients with AI and HO diseases. The variable studied were diagnosis, age, sex, fever, organomegaly, hospital and overall mortality, analytical findings, hospital stay, days from admission to diagnosis and days from diagnosis to the end of the study or death after discharge. Quantitative variables are shown with the median and interquartile range. For the bivariate analysis Wilcoxon and Chi square test were used. Median survival in months and Hazar Ratio (HR) was calculated with the Kaplan Meier plot.ResultsNineteen patients were found diagnosed with MAS, 6 and 9 were due to AI and HO diseases respectively. The AI diseases found were: 3 Systemic Lupus Erythematosus, 2 Adult Still's Disease and 1 disease associated with IgG4. HO diseases found were: 3 acute myeloid leukemias, 2 B cells Not Hogkin Lymphoma (NHL), 1 T anb B cells NHL, 1 Natural Killers cells extranodal lymphoma, 1 myelodysplastic syndrome and 1 gastric plasmacytoma. The table shows the descriptive analysis of 19 patients and the bivariate analysis between AI and HO.The median survival of HO diseases was 1.2 months and AI diseases can not be calculated. The mortality of HO and AI diseases was 77.8% and 16.7% respectively with a p=0.04 in the log rank test. The HR of mortality among HO against AI diseases was 6.84.Table 1All patientsAI diseaseOH diseasep between AI and HOAge (years)56 (32)37.5 (26)66 (15)Female Sex10 (52.6%)4 (66.7%)4 (66.7%)0.205Hospitalization Days from admission to diagnosis38 (69)37.5 (46)61 (59)0.216Days from diagnosis until death or end of study430 (1166)1125 (554)67.5 (410)0.07Organomegaly15 (78.9%)5 (83.3%)7 (77.8%)0.792Hemoglobin (mg/dL)7.3 (1.6)7.4 (2.5)6.4 (1.1)0.0866Platelets (/μL)8000 (15000)11000 (66000)2000 (15000)0.0771Leukocytes (/μL)1010 (2990)2840 (1850)100 (590)0.0771Neutrophils (/μL)360 (1770)1068 (1120)0 (20)0.0074Triglycerides (mg/dL)382 (217)414.5 (307)341 (157)0.44Fibrinogen (mg/dL)213 (304)212 (346)228 (302)0.784Ferritin (μg/L)15971 (31603)15329.5 (38936)16750.5 (43203)0.366GOT144 (365)796 (923)91 (132)0.0251GPT177 (302)581 (409)108 (157)0.0451Mortality during hospitalization8 (42%)1 (16.7%)6 (66.7%)0.057Mortality overall10 (52.6%)1 (16.7%)7 (77.8%)0.02ConclusionsIn the present study the following differences were found: 1) Patients with MAS due to AI diseases have a higher elevated liver enzymes compared to HO disease. 2) Patients with MAS due to HO diseases have a greater pancytopenia compared to AI diseases, especially in leukocytes and neutrophils. 3) Patients with MAS due to HO have a higher mortality compared to AI diseases.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.3006</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.396</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/396.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/396.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Egües Dubuc, C.A.</creatorcontrib><creatorcontrib>Aldasoro Cáceres, V.</creatorcontrib><creatorcontrib>Uriarte Ecenarro, M.</creatorcontrib><creatorcontrib>Meneses Villalba, C.F.</creatorcontrib><creatorcontrib>Errazquin Aguirre, N.</creatorcontrib><creatorcontrib>Hernando Rubio, I.</creatorcontrib><creatorcontrib>Maiz Alonso, O.</creatorcontrib><creatorcontrib>Cancio Fanlo, J.</creatorcontrib><creatorcontrib>Uriarte Isacelaya, E.</creatorcontrib><creatorcontrib>Yagüe Asensio, M.</creatorcontrib><creatorcontrib>Belzunegui Otano, J.</creatorcontrib><title>THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?</title><title>Annals of the rheumatic diseases</title><description>BackgroundSecondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies.ObjectivesTo describe and compare demographics, clinical and laboratories features and mortality of patients diagnosed with secondary MAS due to HO and AI diseases at the Donostia University Hospital.MethodsA cohort of patients diagnosed with MAS was studied by reviewing medical reports in the period Dec/2008-Jan/2015. We analyzed and compared only patients with AI and HO diseases. The variable studied were diagnosis, age, sex, fever, organomegaly, hospital and overall mortality, analytical findings, hospital stay, days from admission to diagnosis and days from diagnosis to the end of the study or death after discharge. Quantitative variables are shown with the median and interquartile range. For the bivariate analysis Wilcoxon and Chi square test were used. Median survival in months and Hazar Ratio (HR) was calculated with the Kaplan Meier plot.ResultsNineteen patients were found diagnosed with MAS, 6 and 9 were due to AI and HO diseases respectively. The AI diseases found were: 3 Systemic Lupus Erythematosus, 2 Adult Still's Disease and 1 disease associated with IgG4. HO diseases found were: 3 acute myeloid leukemias, 2 B cells Not Hogkin Lymphoma (NHL), 1 T anb B cells NHL, 1 Natural Killers cells extranodal lymphoma, 1 myelodysplastic syndrome and 1 gastric plasmacytoma. The table shows the descriptive analysis of 19 patients and the bivariate analysis between AI and HO.The median survival of HO diseases was 1.2 months and AI diseases can not be calculated. The mortality of HO and AI diseases was 77.8% and 16.7% respectively with a p=0.04 in the log rank test. The HR of mortality among HO against AI diseases was 6.84.Table 1All patientsAI diseaseOH diseasep between AI and HOAge (years)56 (32)37.5 (26)66 (15)Female Sex10 (52.6%)4 (66.7%)4 (66.7%)0.205Hospitalization Days from admission to diagnosis38 (69)37.5 (46)61 (59)0.216Days from diagnosis until death or end of study430 (1166)1125 (554)67.5 (410)0.07Organomegaly15 (78.9%)5 (83.3%)7 (77.8%)0.792Hemoglobin (mg/dL)7.3 (1.6)7.4 (2.5)6.4 (1.1)0.0866Platelets (/μL)8000 (15000)11000 (66000)2000 (15000)0.0771Leukocytes (/μL)1010 (2990)2840 (1850)100 (590)0.0771Neutrophils (/μL)360 (1770)1068 (1120)0 (20)0.0074Triglycerides (mg/dL)382 (217)414.5 (307)341 (157)0.44Fibrinogen (mg/dL)213 (304)212 (346)228 (302)0.784Ferritin (μg/L)15971 (31603)15329.5 (38936)16750.5 (43203)0.366GOT144 (365)796 (923)91 (132)0.0251GPT177 (302)581 (409)108 (157)0.0451Mortality during hospitalization8 (42%)1 (16.7%)6 (66.7%)0.057Mortality overall10 (52.6%)1 (16.7%)7 (77.8%)0.02ConclusionsIn the present study the following differences were found: 1) Patients with MAS due to AI diseases have a higher elevated liver enzymes compared to HO disease. 2) Patients with MAS due to HO diseases have a greater pancytopenia compared to AI diseases, especially in leukocytes and neutrophils. 3) Patients with MAS due to HO have a higher mortality compared to AI diseases.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkb9OwzAQxi0EEqXwDpaYA7bjOo4YUIHSVipiKMyWm1xaV41d7ASUjYWX4PF4ElzKwMp0f3Tfd3f6IXROyQWlqbjU1voVtHVpQsIIHSTQbrS_SAkRB6hHuZCxLcgh6hFC0oTnIjtGJyGsY0kklT30-TR5JgPOvt4_pgE3K_CAh7bDd6aqYm4LwDfQvAFYPGwbZ-q6tYCdxxOodeOSR1u4jVt2eNSYfdI4PG5NCbgN2NidZTTTS-uCCdhVeA6Fs6X2HX7QhXfblV7GlUVjXnW0sHje2dK7Gq5P0VGlNwHOfmMfze9HT7eTZPY4nt4OZ8mCsixNSs4KyWmpdVlInUsKkhOeZkwWA8rzjOZVJhiIXC94NWBaSCqiLlvklBGZ9tH53nXr3UsLoVFr13obFyqaE5pJkbM0Tl3tp-LFIXio1NabOj6hKFE7FOoPCrVDoX5QqB2KqBZ79aJe_0v4DahBlkQ</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Egües Dubuc, C.A.</creator><creator>Aldasoro Cáceres, V.</creator><creator>Uriarte Ecenarro, M.</creator><creator>Meneses Villalba, C.F.</creator><creator>Errazquin Aguirre, N.</creator><creator>Hernando Rubio, I.</creator><creator>Maiz Alonso, O.</creator><creator>Cancio Fanlo, J.</creator><creator>Uriarte Isacelaya, E.</creator><creator>Yagüe Asensio, M.</creator><creator>Belzunegui Otano, J.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?</title><author>Egües Dubuc, C.A. ; Aldasoro Cáceres, V. ; Uriarte Ecenarro, M. ; Meneses Villalba, C.F. ; Errazquin Aguirre, N. ; Hernando Rubio, I. ; Maiz Alonso, O. ; Cancio Fanlo, J. ; Uriarte Isacelaya, E. ; Yagüe Asensio, M. ; Belzunegui Otano, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1273-d42c841daadc8a981e84043728c5149719f762e69ab4f52a68162737b912083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egües Dubuc, C.A.</creatorcontrib><creatorcontrib>Aldasoro Cáceres, V.</creatorcontrib><creatorcontrib>Uriarte Ecenarro, M.</creatorcontrib><creatorcontrib>Meneses Villalba, C.F.</creatorcontrib><creatorcontrib>Errazquin Aguirre, N.</creatorcontrib><creatorcontrib>Hernando Rubio, I.</creatorcontrib><creatorcontrib>Maiz Alonso, O.</creatorcontrib><creatorcontrib>Cancio Fanlo, J.</creatorcontrib><creatorcontrib>Uriarte Isacelaya, E.</creatorcontrib><creatorcontrib>Yagüe Asensio, M.</creatorcontrib><creatorcontrib>Belzunegui Otano, J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egües Dubuc, C.A.</au><au>Aldasoro Cáceres, V.</au><au>Uriarte Ecenarro, M.</au><au>Meneses Villalba, C.F.</au><au>Errazquin Aguirre, N.</au><au>Hernando Rubio, I.</au><au>Maiz Alonso, O.</au><au>Cancio Fanlo, J.</au><au>Uriarte Isacelaya, E.</au><au>Yagüe Asensio, M.</au><au>Belzunegui Otano, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>396</spage><pages>396-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundSecondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies.ObjectivesTo describe and compare demographics, clinical and laboratories features and mortality of patients diagnosed with secondary MAS due to HO and AI diseases at the Donostia University Hospital.MethodsA cohort of patients diagnosed with MAS was studied by reviewing medical reports in the period Dec/2008-Jan/2015. We analyzed and compared only patients with AI and HO diseases. The variable studied were diagnosis, age, sex, fever, organomegaly, hospital and overall mortality, analytical findings, hospital stay, days from admission to diagnosis and days from diagnosis to the end of the study or death after discharge. Quantitative variables are shown with the median and interquartile range. For the bivariate analysis Wilcoxon and Chi square test were used. Median survival in months and Hazar Ratio (HR) was calculated with the Kaplan Meier plot.ResultsNineteen patients were found diagnosed with MAS, 6 and 9 were due to AI and HO diseases respectively. The AI diseases found were: 3 Systemic Lupus Erythematosus, 2 Adult Still's Disease and 1 disease associated with IgG4. HO diseases found were: 3 acute myeloid leukemias, 2 B cells Not Hogkin Lymphoma (NHL), 1 T anb B cells NHL, 1 Natural Killers cells extranodal lymphoma, 1 myelodysplastic syndrome and 1 gastric plasmacytoma. The table shows the descriptive analysis of 19 patients and the bivariate analysis between AI and HO.The median survival of HO diseases was 1.2 months and AI diseases can not be calculated. The mortality of HO and AI diseases was 77.8% and 16.7% respectively with a p=0.04 in the log rank test. The HR of mortality among HO against AI diseases was 6.84.Table 1All patientsAI diseaseOH diseasep between AI and HOAge (years)56 (32)37.5 (26)66 (15)Female Sex10 (52.6%)4 (66.7%)4 (66.7%)0.205Hospitalization Days from admission to diagnosis38 (69)37.5 (46)61 (59)0.216Days from diagnosis until death or end of study430 (1166)1125 (554)67.5 (410)0.07Organomegaly15 (78.9%)5 (83.3%)7 (77.8%)0.792Hemoglobin (mg/dL)7.3 (1.6)7.4 (2.5)6.4 (1.1)0.0866Platelets (/μL)8000 (15000)11000 (66000)2000 (15000)0.0771Leukocytes (/μL)1010 (2990)2840 (1850)100 (590)0.0771Neutrophils (/μL)360 (1770)1068 (1120)0 (20)0.0074Triglycerides (mg/dL)382 (217)414.5 (307)341 (157)0.44Fibrinogen (mg/dL)213 (304)212 (346)228 (302)0.784Ferritin (μg/L)15971 (31603)15329.5 (38936)16750.5 (43203)0.366GOT144 (365)796 (923)91 (132)0.0251GPT177 (302)581 (409)108 (157)0.0451Mortality during hospitalization8 (42%)1 (16.7%)6 (66.7%)0.057Mortality overall10 (52.6%)1 (16.7%)7 (77.8%)0.02ConclusionsIn the present study the following differences were found: 1) Patients with MAS due to AI diseases have a higher elevated liver enzymes compared to HO disease. 2) Patients with MAS due to HO diseases have a greater pancytopenia compared to AI diseases, especially in leukocytes and neutrophils. 3) Patients with MAS due to HO have a higher mortality compared to AI diseases.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.3006</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.396
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901786923
source BMJ Journals - NESLi2
title THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T11%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0542%E2%80%85Is%20there%20Any%20Difference%20Between%20Autoimmune%20or%20Hemato-Oncology%20Etiology%20to%20Guide%20us%20in%20the%20Diagnosis%20of%20Secondary%20Macrophage%20Activation%20Syndrome?&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Eg%C3%BCes%20Dubuc,%20C.A.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=396&rft.pages=396-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.3006&rft_dat=%3Cproquest_cross%3E4322503671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901786923&rft_id=info:pmid/&rfr_iscdi=true